$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000154422720000004 Filed on March 11, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019
Revenue	$0.00	$0.00	$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.595M	$4.480M	$17.56M
YoY Change	3.26%	220.0%	41.02%
% of Gross Profit
Research & Development	$7.540M	$8.350M	$27.84M
YoY Change	21.53%	8.02%	93.02%
% of Gross Profit
Depreciation & Amortization	$37.00K	$50.00K	$97.00K
YoY Change	362.5%	-108.33%	203.13%
% of Gross Profit
Operating Expenses	$7.540M	$12.83M	$27.84M
YoY Change	21.53%	142.53%	93.02%
Operating Profit	-$12.14M		-$45.40M
YoY Change	13.87%		68.93%
Interest Expense	$162.0K	$170.0K	$1.038M
YoY Change	-48.57%	-117.35%	-874.63%
% of Operating Profit
Other Income/Expense, Net	-$25.00K	-$40.00K	-$207.0K
YoY Change	25.0%	-180.0%	-617.5%
Pretax Income	-$12.00M	-$12.70M	-$44.57M
YoY Change	15.7%	97.51%	63.99%
Income Tax
% Of Pretax Income
Net Earnings	-$12.00M	-$12.70M	-$44.57M
YoY Change	15.74%	97.2%	63.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$9.755M	-$12.95	-$48.77M
COMMON SHARES
Basic Shares Outstanding	18.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q1	2019 Q4	2019
SHORT-TERM ASSETS
Cash & Short-Term Investments	$58.01M	$62.48M	$62.48M
YoY Change	-13.42%	-19.56%	-19.56%
Cash & Equivalents	$58.01M	$62.48M	$62.48M
Short-Term Investments		$0.00	$0.00
Other Short-Term Assets	$5.081M	$7.300M	$7.378M
YoY Change	20.98%	114.71%	115.86%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$64.62M	$71.13M	$71.13M
YoY Change	-11.11%	-14.73%	-14.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.866M	$3.300M	$3.331M
YoY Change	258.25%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$555.0K	$507.0K	$507.0K
YoY Change	-30.63%	138.03%	-22.24%
Total Long-Term Assets	$3.421M	$3.838M	$3.838M
YoY Change	113.81%	488.65%	488.65%
TOTAL ASSETS
Total Short-Term Assets	$64.62M	$71.13M	$71.13M
Total Long-Term Assets	$3.421M	$3.838M	$3.838M
Total Assets	$68.05M	$74.97M	$74.97M
YoY Change	-8.42%	-10.83%	-10.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.773M	$1.495M	$1.495M
YoY Change	20.57%	-25.18%	-25.18%
Accrued Expenses	$6.738M	$9.066M	$10.82M
YoY Change	-0.91%	18.82%	41.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$258.0K	$208.0K	$208.0K
YoY Change	29.0%	10.05%	10.05%
Total Short-Term Liabilities	$11.21M	$12.52M	$12.52M
YoY Change	20.55%	27.53%	27.53%
LONG-TERM LIABILITIES
Long-Term Debt	$110.0K	$168.0K	$168.0K
YoY Change	-63.33%	-56.14%	-56.14%
Other Long-Term Liabilities	$7.000K	$16.00K	$2.411M
YoY Change	-99.3%	-97.87%	220.61%
Total Long-Term Liabilities	$117.0K	$184.0K	$2.579M
YoY Change	-91.0%	-83.79%	127.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.21M	$12.52M	$12.52M
Total Long-Term Liabilities	$117.0K	$184.0K	$2.579M
Total Liabilities	$13.41M	$15.10M	$16.42M
YoY Change	4.73%	37.87%	25.15%
SHAREHOLDERS EQUITY
Retained Earnings	-$220.7M	-$208.7M
YoY Change		27.16%
Common Stock	$19.00K	$18.00K
YoY Change		38.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.83M	-$50.36M	$58.55M
YoY Change
Total Liabilities & Shareholders Equity	$68.05M	$74.97M	$74.97M
YoY Change	-8.42%	-10.83%	-10.83%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019
OPERATING ACTIVITIES
Net Income	-$12.00M	-$12.70M	-$44.57M
YoY Change	15.74%	97.2%	63.9%
Depreciation, Depletion And Amortization	$37.00K	$50.00K	$97.00K
YoY Change	362.5%	-108.33%	203.13%
Cash From Operating Activities	-$10.16M	-$11.69M	-$41.22M
YoY Change	-4.15%	441.2%	74.32%
INVESTING ACTIVITIES
Capital Expenditures	$26.00K	$40.00K	$397.0K
YoY Change	160.0%	0.0%	1002.78%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities	$0.00	$0.00	$4.385M
YoY Change	-100.0%	-100.0%	122.82%
Cash From Investing Activities	-$26.00K	-$30.00K	$3.988M
YoY Change	-100.87%	-99.92%	106.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$5.521M		$26.69M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$5.589M	26.86M	$26.94M
YoY Change	-9415.0%	-65.45%	-65.34%
NET CHANGE
Cash From Operating Activities	-$10.16M	-11.69M	-$41.22M
Cash From Investing Activities	-$26.00K	-30.00K	$3.988M
Cash From Financing Activities	$5.589M	26.86M	$26.94M
Net Change In Cash	-$4.635M	15.14M	-$10.26M
YoY Change	-39.8%	-61.96%	-118.27%
FREE CASH FLOW
Cash From Operating Activities	-$10.16M	-$11.69M	-$41.22M
Capital Expenditures	$26.00K	$40.00K	$397.0K
Free Cash Flow	-$10.19M	-$11.73M	-$41.62M
YoY Change	-4.0%	433.18%	75.73%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Entity Registrant Name EntityRegistrantName	Millendo Therapeutics, Inc.
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73770000	USD
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q2	dei	Entity Public Float EntityPublicFloat	124400000	USD
CY2019	dei	Entity Small Business EntitySmallBusiness	true
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18266545	shares
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62478000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73286000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1034000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	45000	USD
CY2019Q4	us-gaap	Marketable Securities MarketableSecurities	0	USD
CY2018Q4	us-gaap	Marketable Securities MarketableSecurities	4385000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6344000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3373000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1276000	USD
CY2018Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	2333000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	71132000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	83422000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	439000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3331000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	507000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	213000	USD
CY2019Q4	us-gaap	Assets Assets	74970000	USD
CY2018Q4	us-gaap	Assets Assets	84074000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	208000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	189000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1495000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1998000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9066000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7630000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1751000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12520000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9817000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	168000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	383000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2395000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	752000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	15099000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	10952000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18266545	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18266545	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13357999	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13357999	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	267018000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	234876000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208654000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164086000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	165000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	148000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	58547000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	70951000	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	1324000	USD
CY2018Q4	us-gaap	Minority Interest MinorityInterest	2171000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	59871000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73122000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74970000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	84074000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	27843000	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14425000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17556000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8691000	USD
CY2019	us-gaap	Other General Expense OtherGeneralExpense	0	USD
CY2018	us-gaap	Other General Expense OtherGeneralExpense	3758000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-45399000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-26874000	USD
CY2019	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	1038000	USD
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-134000	USD
CY2019	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-207000	USD
CY2018	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	-169000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-44568000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-27177000	USD
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	15000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-44568000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-27192000	USD
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.25
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-17.58
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13706744	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1547051	shares
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	17000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	140000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44551000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27052000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-128523000	USD
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	132922000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	99000	USD
CY2018	mlnd	Stock Issued During Period Value Conversion Of Convertible Debt StockIssuedDuringPeriodValueConversionOfConvertibleDebt	7724000	USD
CY2018	mlnd	Stock Issued During Period Value New Issues Before Merger StockIssuedDuringPeriodValueNewIssuesBeforeMerger	20054000	USD
CY2018	mlnd	Record Pre Merger Equity And Elimination Of Historical Accumulated Deficit Value RecordPreMergerEquityAndEliminationOfHistoricalAccumulatedDeficitValue	37994000	USD
CY2018	mlnd	Stock Issued During Period Value New Issues After Merger StockIssuedDuringPeriodValueNewIssuesAfterMerger	18687000	USD
CY2018	us-gaap	Noncontrolling Interest Increase From Sale Of Parent Equity Interest NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest	9790000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1427000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	140000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-27192000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	73122000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	361000	USD
CY2019	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	20000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26491000	USD
CY2019	mlnd	Stock Issued During Period Value Warrants Exercised And Forfeited StockIssuedDuringPeriodValueWarrantsExercisedAndForfeited	111000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4317000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	17000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-44568000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	59871000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-44568000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-27177000	USD
CY2019	us-gaap	Depreciation Depreciation	97000	USD
CY2018	us-gaap	Depreciation Depreciation	32000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4317000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1427000	USD
CY2019	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	0	USD
CY2018	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	871000	USD
CY2019	mlnd	Non Cash Interest NonCashInterest	0	USD
CY2018	mlnd	Non Cash Interest NonCashInterest	204000	USD
CY2019	mlnd	Amortization Operating Lease Right Of Use Asset AmortizationOperatingLeaseRightOfUseAsset	955000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-40000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-30000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	698000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2524000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-66000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-469000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	320000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	281000	USD
CY2018	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3240000	USD
CY2019	mlnd	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-1233000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-41222000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23647000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	397000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	4385000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2492000	USD
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	524000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3988000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1932000	USD
CY2019	mlnd	Cash Acquired From Acquisition Financing Activities CashAcquiredFromAcquisitionFinancingActivities	0	USD
CY2018	mlnd	Cash Acquired From Acquisition Financing Activities CashAcquiredFromAcquisitionFinancingActivities	33316000	USD
CY2019	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	8000000	USD
CY2019	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	202000	USD
CY2018	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	169000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	26688000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	-15000	USD
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	38756000	USD
CY2019	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2018	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	1351000	USD
CY2019	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	0	USD
CY2018	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	808000	USD
CY2019	mlnd	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	472000	USD
CY2018	mlnd	Proceeds From Stock Options And Warrants Exercised ProceedsFromStockOptionsAndWarrantsExercised	0	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26943000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	77744000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10258000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	56147000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17623000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63512000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73770000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	USD
CY2019	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2018	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	132922000	USD
CY2019	mlnd	Reclassification Of Preferred Stock Warrant Liability ReclassificationOfPreferredStockWarrantLiability	0	USD
CY2018	mlnd	Reclassification Of Preferred Stock Warrant Liability ReclassificationOfPreferredStockWarrantLiability	99000	USD
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7724000	USD
CY2019	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	0	USD
CY2018	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	9790000	USD
CY2019	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	197000	USD
CY2018	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	15000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3414000	USD
CY2019Q4	mlnd	Number Of Product Candidates NumberOfProductCandidates	3	product
CY2018Q4	mlnd	Business Combination Exchange Ratio BusinessCombinationExchangeRatio	0.0744
CY2018Q4	mlnd	Business Combination Exchange Ratio BusinessCombinationExchangeRatio	0.0744
CY2019Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	63500000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208700000	USD
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of estimates</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the Consolidated Financial Statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary.</span></div>
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of credit risk</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents, marketable securities and restricted cash. The Company generally invests its cash in deposits with high credit quality financial institutions. Deposits at banks may exceed the insurance provided on such deposits. Additionally, the Company performs periodic evaluations of the relative credit standing of these financial institutions.</span></div>
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62478000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	73286000	USD
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1034000	USD
CY2018Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	45000	USD
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	0	USD
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	439000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63512000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	73770000	USD
CY2019	mlnd	Reduction Of Research And Development Expenses ReductionOfResearchAndDevelopmentExpenses	1200000	USD
CY2018	mlnd	Reduction Of Research And Development Expenses ReductionOfResearchAndDevelopmentExpenses	1400000	USD
CY2019	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	1300000	USD
CY2018	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	2300000	USD
CY2019Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	0	USD
CY2018	mlnd	Deferred Offering Cost Expensed DeferredOfferingCostExpensed	900000	USD
CY2019	mlnd	Deferred Offering Cost Expensed DeferredOfferingCostExpensed	0	USD
CY2019	mlnd	Global Intangible Low Taxed Income Cost Incurred GlobalIntangibleLowTaxedIncomeCostIncurred	0	USD
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2611298	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1938131	shares
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Severance Costs1 SeveranceCosts1	1800000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	0	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7630000	USD
CY2018Q3	us-gaap	Debt Instrument Interest Rate During Period DebtInstrumentInterestRateDuringPeriod	0.060
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2042000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3537000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2929000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1140000	USD
CY2019Q4	mlnd	Preclinical And Clinical Costs PreclinicalAndClinicalCosts	1820000	USD
CY2018Q4	mlnd	Preclinical And Clinical Costs PreclinicalAndClinicalCosts	1811000	USD
CY2019Q4	mlnd	Lease Termination Current LeaseTerminationCurrent	0	USD
CY2018Q4	mlnd	Lease Termination Current LeaseTerminationCurrent	630000	USD
CY2019Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1423000	USD
CY2018Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	0	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	852000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	512000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9066000	USD
CY2019	mlnd	Percent Of Reimbursement Annuity PercentOfReimbursementAnnuity	0.20
CY2018Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	8000000.0	USD
CY2018Q3	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	499504	shares
CY2018Q3	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	500000	USD
CY2018Q3	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	400000	USD
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	200000	USD
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	52000	USD
	mlnd	Number Of Non Cancelable Operating Lease Agreements NumberOfNonCancelableOperatingLeaseAgreements	2	agreement
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4100000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.070
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y8M15D
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	200000	USD
CY2019	mlnd	Operating Lease Payments Included In Measurement Lease Liability OperatingLeasePaymentsIncludedInMeasurementLeaseLiability	1500000	USD
CY2019	us-gaap	Sublease Income SubleaseIncome	300000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1803000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	805000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	828000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	851000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	347000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	45000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4679000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	533000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	4146000	USD
CY2019	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2019	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03
CY2019	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	200000	USD
CY2018	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	100000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2018Q4	mlnd	Business Combination Exchange Ratio BusinessCombinationExchangeRatio	0.0744
CY2018Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1230158	shares
CY2018Q4	us-gaap	Share Price SharePrice	16.26
CY2018Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18700000	USD
CY2018Q4	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	499504	shares
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	97225	shares
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2018Q4	mlnd	Number Of Votes Per Share NumberOfVotesPerShare	1	vote
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2019Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2018Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	6759109	shares
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2018	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	0
CY2019	us-gaap	Preferred Stock Dividends Per Share Cash Paid PreferredStockDividendsPerShareCashPaid	0
CY2018	us-gaap	Preferred Stock Dividends Per Share Cash Paid PreferredStockDividendsPerShareCashPaid	0
CY2019	us-gaap	Preferred Stock Dividends Per Share Declared PreferredStockDividendsPerShareDeclared	0
CY2019Q4	mlnd	Preferred Stock Multiplier For Converted Value PreferredStockMultiplierForConvertedValue	3
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	17125	shares
CY2019Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	16.93
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4317000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1427000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward	10 years
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	703479	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.91
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M18D
CY2018	mlnd	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Merger Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromMergerNumber	423316	shares
CY2018	mlnd	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Merger Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromMergerWeightedAverageExercisePrice	78.70
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	776140	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	15.82
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	72049	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	16.40
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	66599	shares
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.54
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1764287	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.81
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1225901	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.73
CY2019	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	97225	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.71
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	394357	shares
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	40.42
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2498606	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.18
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	984264	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	26.42
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2498606	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	17.18
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1514342	shares
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	9200000	USD
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	700000	USD
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1200000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1200000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.74
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.72
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y7D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.80
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.66
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0222
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0277
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q4	us-gaap	Share Price SharePrice	9.73
CY2018Q4	us-gaap	Share Price SharePrice	15.82
CY2019Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	13600000	USD
CY2018Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	12200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	96378000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	87446000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	13404000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	12196000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4107000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5209000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	414000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1233000	USD
CY2019Q4	mlnd	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	742000	USD
CY2019Q4	mlnd	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	934000	USD
CY2019Q4	mlnd	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	855000	USD
CY2018Q4	mlnd	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	1031000	USD
CY2019Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	10000	USD
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Other Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets	936000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	115360000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	108051000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115360000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	108051000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7300000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.041
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.010
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.041
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.087
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.033
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.027
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.050
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.164
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.227
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	8000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21500000	USD

Files In Submission

Name	View Source	Status
0001544227-20-000004-index-headers.html	Edgar Link	pending
0001544227-20-000004-index.html	Edgar Link	pending
0001544227-20-000004.txt	Edgar Link	pending
0001544227-20-000004-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mlnd-20191231.htm	Edgar Link	pending
mlnd-20191231.xsd	Edgar Link	pending
mlnd-20191231xex1016.htm	Edgar Link	pending
mlnd-20191231xex1029.htm	Edgar Link	pending
mlnd-20191231xex108.htm	Edgar Link	pending
mlnd-20191231xex211.htm	Edgar Link	pending
mlnd-20191231xex231.htm	Edgar Link	pending
mlnd-20191231xex311.htm	Edgar Link	pending
mlnd-20191231xex312.htm	Edgar Link	pending
mlnd-20191231xex321.htm	Edgar Link	pending
mlnd-20191231xex46.htm	Edgar Link	pending
mlnd-20191231_cal.xml	Edgar Link	unprocessable
mlnd-20191231_def.xml	Edgar Link	unprocessable
mlnd-20191231_g1.jpg	Edgar Link	pending
mlnd-20191231_g2.jpg	Edgar Link	pending
mlnd-20191231_g3.jpg	Edgar Link	pending
mlnd-20191231_g4.jpg	Edgar Link	pending
mlnd-20191231_g5.jpg	Edgar Link	pending
mlnd-20191231_g6.jpg	Edgar Link	pending
mlnd-20191231_htm.xml	Edgar Link	completed
mlnd-20191231_lab.xml	Edgar Link	unprocessable
mlnd-20191231_pre.xml	Edgar Link	unprocessable
mlnd-201912x31xex1017.htm	Edgar Link	pending
mlnd-201912x31xex1043.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2020 Q1 Form 10-K Financial Statement

#000154422720000004 Filed on March 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2020 Q1 Form 10-K Financial Statement

#000154422720000004 Filed on March 11, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst